384 related articles for article (PubMed ID: 11268287)
1. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter.
Xie X; Zhao X; Liu Y; Young CY; Tindall DJ; Slawin KM; Spencer DM
Hum Gene Ther; 2001 Mar; 12(5):549-61. PubMed ID: 11268287
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
3. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.
Yu DC; Sakamoto GT; Henderson DR
Cancer Res; 1999 Apr; 59(7):1498-504. PubMed ID: 10197620
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
Xie X; Zhao X; Liu Y; Zhang J; Matusik RJ; Slawin KM; Spencer DM
Cancer Res; 2001 Sep; 61(18):6795-804. PubMed ID: 11559553
[TBL] [Abstract][Full Text] [Related]
5. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
6. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors.
Wu L; Matherly J; Smallwood A; Adams JY; Billick E; Belldegrun A; Carey M
Gene Ther; 2001 Sep; 8(18):1416-26. PubMed ID: 11571582
[TBL] [Abstract][Full Text] [Related]
7. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter.
Cleutjens KB; van der Korput HA; van Eekelen CC; van Rooij HC; Faber PW; Trapman J
Mol Endocrinol; 1997 Feb; 11(2):148-61. PubMed ID: 9013762
[TBL] [Abstract][Full Text] [Related]
8. Recombinant adenovirus mediated prostate-specific enzyme pro-drug gene therapy regulated by prostate-specific membrane antigen (PSMA) enhancer/promoter.
Zeng H; Wei Q; Huang R; Chen N; Dong Q; Yang Y; Zhou Q
J Androl; 2007; 28(6):827-35. PubMed ID: 17522418
[TBL] [Abstract][Full Text] [Related]
9. Interactive effects of triiodothyronine and androgens on prostate cell growth and gene expression.
Zhang S; Hsieh ML; Zhu W; Klee GG; Tindall DJ; Young CY
Endocrinology; 1999 Apr; 140(4):1665-71. PubMed ID: 10098501
[TBL] [Abstract][Full Text] [Related]
10. The EZC-prostate model: noninvasive prostate imaging in living mice.
Xie X; Luo Z; Slawin KM; Spencer DM
Mol Endocrinol; 2004 Mar; 18(3):722-32. PubMed ID: 14684850
[TBL] [Abstract][Full Text] [Related]
11. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.
Lillehammer T; Tveito S; Engesaeter BO; Fodstad O; Maelandsmo GM; Engebraaten O
Cancer Gene Ther; 2005 Nov; 12(11):864-72. PubMed ID: 15891771
[TBL] [Abstract][Full Text] [Related]
12. Prostate-tumor targeting of gene expression by lentiviral vectors containing elements of the probasin promoter.
Yu D; Jia WW; Gleave ME; Nelson CC; Rennie PS
Prostate; 2004 Jun; 59(4):370-82. PubMed ID: 15065085
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.
Li X; Zhang YP; Kim HS; Bae KH; Stantz KM; Lee SJ; Jung C; Jiménez JA; Gardner TA; Jeng MH; Kao C
Cancer Res; 2005 Mar; 65(5):1941-51. PubMed ID: 15753394
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific targeting using PSA promoter-based lentiviral vectors.
Yu D; Chen D; Chiu C; Razmazma B; Chow YH; Pang S
Cancer Gene Ther; 2001 Sep; 8(9):628-35. PubMed ID: 11593331
[TBL] [Abstract][Full Text] [Related]
15. Functional promoter testing using a modified lentiviral transfer vector.
Geller SF; Ge PS; Visel M; Greenberg KP; Flannery JG
Mol Vis; 2007 May; 13():730-9. PubMed ID: 17563724
[TBL] [Abstract][Full Text] [Related]
16. Construction of a targeting adenoviral vector carrying AFP promoter for expressing EGFP gene in AFP-producing hepatocarcinoma cell.
Shi YJ; Gong JP; Liu CA; Li XH; Mei Y; Mi C; Huo YY
World J Gastroenterol; 2004 Jan; 10(2):186-9. PubMed ID: 14716819
[TBL] [Abstract][Full Text] [Related]
17. Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival.
Zhang L; Brereton HM; Hahn M; Froscio M; Tilley WD; Brown MP; Barritt GJ
Cancer Gene Ther; 2003 Aug; 10(8):611-25. PubMed ID: 12872143
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.
Ylikoski A; Karp M; Pettersson K; Lilja H; Lövgren T
J Mol Diagn; 2001 Aug; 3(3):111-22. PubMed ID: 11486050
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of double gene construct for rapid identification of transgenic mice exhibiting tissue-specific gene expression.
Sato M; Watanabe T; Oshida A; Nagashima A; Miyazaki JI; Kimura M
Mol Reprod Dev; 2001 Dec; 60(4):446-56. PubMed ID: 11746955
[TBL] [Abstract][Full Text] [Related]
20. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice.
Xu L; Daly T; Gao C; Flotte TR; Song S; Byrne BJ; Sands MS; Parker Ponder K
Hum Gene Ther; 2001 Mar; 12(5):563-73. PubMed ID: 11268288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
